BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7775135)

  • 1. Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck.
    Huber MH; Dimery IW; Benner SE; Lippman SM; Shirinian M; Esparaz B; Frenning D; Guillory-Perez C; Hong WK
    Invest New Drugs; 1994; 12(4):327-31. PubMed ID: 7775135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy.
    Edelman MJ; Gandara DR; Perez EA; Lau D; Lauder I; Turrell C; Uhrich M; Meyers F
    Invest New Drugs; 1998; 16(1):69-75. PubMed ID: 9740546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
    Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
    Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.
    Gandara DR; Edelman MJ; Crowley JJ; Lau DH; Livingston RB
    Cancer Chemother Pharmacol; 1997; 41(1):75-8. PubMed ID: 9443617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of edatrexate in advanced head and neck cancer. A Southwest Oncology Group study.
    Kuebler JP; Benedetti J; Schuller DE; Ensley J; Grunberg SM; Muirhead MJ; Richert-Boe KE; Marshall ME
    Invest New Drugs; 1994; 12(4):341-4. PubMed ID: 7775138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy.
    Lee JS; Murphy WK; Shirinian MH; Pang A; Hong WK
    Cancer Chemother Pharmacol; 1991; 28(3):199-204. PubMed ID: 1649705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
    Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
    J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Shin DM; Khuri FR; Glisson BS; Ginsberg L; Papadimitrakopoulou VM; Clayman G; Lee JJ; Ang KK; Lippman SM; Hong WK
    Cancer; 2001 Apr; 91(7):1316-23. PubMed ID: 11283932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
    Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study.
    Fountzilas G; Athanassiadis A; Samantas E; Skarlos D; Kalogera-Fountzila A; Nikolaou A; Bacoyiannis H; Stathopoulos G; Kosmidis P; Daniilidis J
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-65-S2-67. PubMed ID: 9045340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
    Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.
    Schornagel JH; Verweij J; de Mulder PH; Cognetti F; Vermorken JB; Cappelaere P; Armand JP; Wildiers J; de Graeff A; Clavel M
    J Clin Oncol; 1995 Jul; 13(7):1649-55. PubMed ID: 7602354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination cisplatin and carboplatin in advanced squamous cell carcinoma of the head and neck.
    Patton JF; Powell BL; White DR; Russell GB; Inabinet RT; Muss HB
    Cancer Invest; 1996; 14(2):98-102. PubMed ID: 8597908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Bourhis J; Rivera F; Mesia R; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez-Pousa A; Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A
    J Clin Oncol; 2006 Jun; 24(18):2866-72. PubMed ID: 16717293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edatrexate studies in non-small cell lung cancer.
    Gralla RJ
    Lung Cancer; 1995 Apr; 12 Suppl 1():S187-91. PubMed ID: 7551928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Adamo V; Maisano R; Pergolizzi S; Altavilla G; Caristi N; Chiofalo G; Scimone A; Settineri N
    J Chemother; 1997 Feb; 9(1):72-6. PubMed ID: 9106022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.
    Dimery IW; Brooks BJ; Winn R; Martin T; Shirinian M; Hong WK
    J Clin Oncol; 1991 Nov; 9(11):1939-44. PubMed ID: 1941052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck.
    Pivot X; Cals L; Cupissol D; Guardiola E; Tchiknavorian X; Guerrier P; Merad L; Wendling JL; Barnouin L; Savary J; Thyss A; Schneider M
    Oncology; 2001; 60(1):66-71. PubMed ID: 11150911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC Phase II study.
    Fesneau M; Pointreau Y; Chapet S; Martin L; Pommier P; Alfonsi M; Laguerre B; Feham N; Berger C; Garaud P; Calais G
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):154-63. PubMed ID: 19386430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
    Papadimitrakopoulou VA; Dimery IW; Lee JJ; Perez C; Hong WK; Lippman SM
    Cancer J Sci Am; 1997; 3(2):92-9. PubMed ID: 9099459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.